FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.
The FDA has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), a new subcutaneous injection formulation of Opdivo.
Nivolumab biosimilar is under clinical development by Amgen and currently in Phase III for Metastatic Melanoma.
Chairman of the Board, Wei Fu, informed the Company of his intent to purchase up to $2,000,000 of the Company's American ...
On December 27, 2024, subcutaneous nivolumab (Opdivo Qvantig) was approved by the FDA in all previously approved adult solid ...
The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for ...
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Osteosarcoma. According to GlobalData, Phase II drugs for Osteosarcoma have a 13% phase transition success ...
Opdivo Qvantig combines nivolumab, a programmed death receptor-1 (PD-1)-blocking antibody, with hyaluronidase, an endoglycosidase that increases the permeability of the SC tissue. Opdivo was ...
The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on ...
High Omega-3, Low Omega-6 Diet With Fish Oil for Men With Prostate Cancer on Active Surveillance: The CAPFISH-3 Randomized Clinical Trial Nivolumab plus relatlimab demonstrated a statistically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback